

Biogen
"Pioneering biotechnology company transforming lives through breakthrough neurological medicines"
About Biogen
Biogen is a leading biotechnology company founded in 1978 that develops innovative medicines for people living with serious neurological, immunological, and rare diseases. The company applies deep understanding of human biology to advance first-in-class treatments that transform patient outcomes in areas where effective therapies remain scarce. For nearly five decades, Biogen has maintained its commitment to bold scientific exploration, creating medicines for hard-to-treat conditions including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and lupus. Operating globally with therapies in over 80 countries, the company continues expanding its pipeline whilst supporting patients through dedicated access programmes.


7500
Team Members
1978
Founded
Public
Funding
Hybrid
Work Environment
A world where breakthrough science eliminates the burden of neurological and rare diseases, transforming fear and limitation into possibility and hope for patients and families everywhere.
Biogen pioneers innovative science to deliver new medicines that transform patients' lives and create value for shareholders and communities.